Loading market dashboard
John Hancock Preferred Income Fund
HPIFinancial ServicesNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
/PRNewswire/ - The John Hancock closed-end funds listed below declared their monthly distributions today as follows: Declaration Date: June 1, 2026 Ex Date:
[url="]First American Data and Analytics[/url], a leading national provider of property-centric information, risk management and valuation solutions and a divisi
BOSTON, May 19, 2026 /PRNewswire/ - The John Hancock Closed-End Funds listed in the table below announced earnings1 for the three months ended April 30, 2026. The same data for the comparable three-month period ended April 30, 2025 is also available below.
BOSTON, May 1, 2026 /PRNewswire/ - The John Hancock closed-end funds listed below declared their monthly distributions today as follows: Declaration Date: May 1, 2026Ex Date: May 11, 2026Record Date: May 11, 2026Payment Date: May 29, 2026 Ticker Fund Name Distribution Per Share Change From Previous Distribution Market Price as of 4/30/2026 Annualized Current Distribution Rate at Market HPI Preferred Income Fund I $0.1235 - $16.35 9.06 % HPF Preferred Income Fund II $0.1235 - $16.08 9.22 % HPS Preferred Income Fund III $0.1100 - $14.83 8.90 % PDT Premium Dividend Fund $0.0825 - $13.23 7.48 % HTD Tax-Advantaged Dividend Income Fund $0.1580 - $25.94 7.31 % John Hancock Premium Dividend Fund Premium Dividend Fund (the "Fund") declared its monthly distribution pursuant to the Fund's managed distribution plan (the "PDT Plan"). Under the PDT Plan, the Fund makes monthly distributions of an amount equal to $0.0825 per share.
BOSTON, April 1, 2026 /PRNewswire/ - The John Hancock closed-end funds listed below declared their monthly distributions today as follows
John Hancock Preferred Income Fund is now rated a buy, trading at a 0.26% premium to NAV and offering a 9.7% yield. HPI's income-focused strategy leverages preferred securities and corporate bonds, with 59.94% investment-grade exposure and aggressive 38.64% leverage. Performance is poised to improve as interest rates decline, enhancing operating spreads and supporting higher valuations, especially with AI infrastructure-linked utilities exposure.
Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HDV candidate ABI-6250 are expected to initiate by end of 2026, with interim catalysts ahead. ABI-6250 aims to be the first oral HDV therapy, addressing an unmet need with positive phase 1a data and a favorable safety profile supporting daily dosing.
